Company intelligence / Profile preview

Arteaus Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Arteaus successfully developed galcanezumab (Emgality), an anti-CGRP monoclonal antibody for migraine prevention. The company led initial clinical proof-of-concept studies and completed a Phase 2 study in migraine prevention. Emgality was FDA-approved in September 2018 and EMA-approved in November 2018.

Therapeutic areas: Neurology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Eli Lilly and Company

Beyond the preview

Go deeper on Arteaus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arteaus Therapeutics.

Explore the full profile